HER-2/neu immunotherapies: Take two – get more: optimization strategies for HER-2/neu-based immunotherapies inhibiting carcinogenesis

Invasive pleomorphic lobular carcinoma, negative for ER, PR and Her/2neu--a case report.

Pleomorphic variant of lobular carcinoma is a recently described variant of invasive lobular carcinoma. It is reported to be positive for estrogen receptors and progesterone receptors and over express Her2/neu in most cases. We present here a case of invasive variant of pleomorphic lobular carcinoma with coexisting classic and pleomorphic variants of lobular carcinoma in situ along with focal d...

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?

We report here a 44-year-old Moroccan man with resectable gastric adenocarcinoma with overexpression of human epidermal growth factor receptor 2 (HER2) by immunohistochemistry who was treated with trastuzumab in combination with chemotherapy in perioperative setting. He received 3 cycles of neoadjuvant chemotherapy consisting of trastuzumab, oxaliplatin, and capecitabine. Afterwards, he receive...

Adjunct immunotherapies for tuberculosis.

The continued spread of multidrug-resistant (MDR) tuberculosis and extensively drug-resistant tuberculosis poses a major threat to global tuberculosis control. Treatment is complex and requires longer use of more-expensive, less effective, and toxic anti-tuberculosis drugs, which results in high morbidity and mortality. The poor treatment outcomes and the slow progress in the development and ev...

HER2-Driven Carcinogenesis: New Mouse Models for Novel Immunotherapies

Epigenetic Strategies to Boost Cancer Immunotherapies

Recently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select responsive patients. Emerging data suggest that epigenetic drugs can improve the responses to immunoth...